Summary
Samenvatting oncologie
- Course
- Institution
Dit is een samenvatting van het deel 'oncologie' van het vak 'hemato-oncologie Het bevat alle leerstof van de powerpoints van oa prof Schöffski, prof Haustermans...
[Show more]
Seller
Follow
zGNK
Reviews received
Content preview
INHOUDHoofdstuk 1: inleiding kanker ...............................................................................................................3
Epidemiologie (wereldwijd) ...............................................................................................................3
Trends ..........................................................................................................................................3
Risico op kanker (België) ...................................................................................................................3
Etiologie...........................................................................................................................................4
Preventie .........................................................................................................................................6
Primair .........................................................................................................................................6
Secundair .....................................................................................................................................6
Symptomatologie .............................................................................................................................6
Hoofdstuk 2: systemische, antineoplastische therapie ..........................................................................8
Inleding: systemsische kankertherapie ..............................................................................................8
Principes .........................................................................................................................................9
Praktijk ............................................................................................................................................9
Procedures ................................................................................................................................. 10
Evaluatie .................................................................................................................................... 10
Behandelingsintervallen en therapiefasen .................................................................................... 11
Producten ...................................................................................................................................... 11
Chemotherapie .......................................................................................................................... 11
Hormoontherapie ....................................................................................................................... 12
Target therapie ........................................................................................................................... 12
Immuuntherapie ......................................................................................................................... 13
Multimodale therapie .................................................................................................................. 13
Nevenwerkingen............................................................................................................................. 13
Chemotherapie .......................................................................................................................... 13
Hormoontherapie ....................................................................................................................... 14
Target therapie ........................................................................................................................... 14
Immuuntherapie ......................................................................................................................... 14
Worst case ................................................................................................................................. 14
Supportieve behandeling ................................................................................................................ 14
Hoofdstuk 3: erfelijke voorbeschiktheid tot kanker ............................................................................... 15
Ontstaan van kanker ....................................................................................................................... 15
Familiaal voorkomen ...................................................................................................................... 16
Familiaal kankersyndroom .......................................................................................................... 16
Erfelijke borst- en ovariumkanker (HBOC) ........................................................................................ 17
Borstkanker ................................................................................................................................ 17
Inhoud 1
, Diagnostisch genetisch onderzoek HBOC .................................................................................... 18
Predictief genetisch onderzoek HBOC .......................................................................................... 18
Familiaal colorectaal kanker (CRC) ................................................................................................. 19
Lynch syndroom ......................................................................................................................... 19
Familiaal adenomateuze polyposis (FAP) ..................................................................................... 20
MUTYH-associated polyposis (MAP)............................................................................................. 20
Zeldzame familiale kankersyndromen ............................................................................................. 20
Li Fraumeni syndroom ................................................................................................................. 20
Andere ....................................................................................................................................... 20
Hoofdstuk 4: radiotherapie ................................................................................................................. 23
Inleiding ......................................................................................................................................... 23
Straling .......................................................................................................................................... 23
Proces ........................................................................................................................................... 24
Types ............................................................................................................................................. 26
Protontherapie ........................................................................................................................... 26
R’en van radiologie ......................................................................................................................... 27
Radiosensitiviteit ........................................................................................................................ 27
Repair ........................................................................................................................................ 27
Repopulatie ................................................................................................................................ 28
Redistributie ............................................................................................................................... 29
Reoxygenatie .............................................................................................................................. 29
Fractionatie ................................................................................................................................... 29
Target therapie ............................................................................................................................... 30
Inhoud 2
, ONCOLOGIE
HOOFDSTUK 1: INLEIDING KANKER
EPIDEMIOLOGIE (WERELDWIJD)
Incidentie = aantal nieuwe diagnosen per 100000/jaar (heel zeldzaam: 1/1000000)
- Duidelijke verschillen tussen ontwikkelde landen onderling -> ander type primeert
- Duidelijke verschillen tussen ontwikkelde en ontwikkelingslanden
- Mannen: - Vrouwen:
1. Longkanker 1. Borstkanker
2. Prostaatkanker 2. Darmkanker
3. Darmkanker 3. Longkanker
Prevalentie = aantal patiënten met een bepaalde aandoening op een gegeven moment
Mortaliteit = aantal overlijdens per 100000/jaar => elk jaar 8 miljoen
- Mannen: - Vrouwen:
1. Longkanker 1. Borstkanker (door heel hoge incidentie!)
2. Leverkanker 2. Longkanker
3. Maagkanker 3. Darmkanker
TRENDS
- Grote piek prostaatkanker → door invoeren screening PSA
o Vaak overbehandeling, want PSA kan door heel veel zaken gestegen zijn
o Biopsie bij pos PSA test voor bevestiging
- Grote piek longkanker bij mannen met momenteel daling mortaliteit
o Plateau bij vrouwen door nog moeten komen -> vrouwen later beginnen met roken
- Daling maagkanker → door eradicatie H pylori + betere bewaring van voedsel
o Minder conservering door roken of pekelen
o Minder opname carcinogenen (nitraat, nitriet)
o Minder opname bacteriën en schimmels (aflatoxine)
RISICO OP KANKER (BELGIË)
Incidentie
- 1/3 bij mannen 1/4 bij vrouwen ➔ correlatie tussen incidentie en leeftijd
o Meeste patiënten > 60 jaar; uitzonderlijk bij kinderen (0,6%)
o Kinderen: leukemie, hersenen, nieren paradox: veel mensen denken veel voorkomen
o Adolescenten: hematologisch, hersenen, huid (melanoom), testis, baarmoederhals
o Ouderen: major killers (zie wereldwijd)
- Hogere incidentie tov andere Europese landen voor: prostaatkanker, borstkanker, hoofd- en
halskanker
- Meest voorkomende kankers zijn die van wereldwijd
Hoofdstuk 1: inleiding kanker 3
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller zGNK. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $7.47. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
73314 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now